HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ODE V deputy director

This article was originally published in The Tan Sheet

Executive Summary

Brian Harvey, MD/PhD, appointed deputy director, Office of Drug Evaluation V, effective May 30, FDA announces. Harvey joined FDA in 1995 as a medical officer and has served in clinical review and management positions at both CDRH and CBER. He is involved in FDA interagency collaborations with NIH, CDC and has served as FDA liaison to several professional societies and industry groups, agency notes. Harvey graduated from Middlebury College and received a PhD in biochemistry and an MD at the University of Connecticut. He will report to Jonca Bull, MD, who became director of ODE V roughly a year ago (1"The Tan Sheet" June 3, 2002, p. 13). One of Harvey's first tasks involving the Division of OTC Drug Products could be attending the upcoming NDAC meeting on ipecac...

You may also be interested in...



ODE V Permanent Director Bull Brings Women’s Health, Analgesics Expertise

Jonca Bull, MD, will tackle Rx-to-OTC switch issues head-on in her first week as permanent director of FDA's Office of Drug Evaluation V

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

In Case You Missed It … News On China Patents, EMA Chief, And More

We clean out your Martin Luther King Day inbox so you don't have to.

Topics

UsernamePublicRestriction

Register

RS128760

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel